An international team of researchers led by the University of British Columbia (UBC) has made a scientific advance they hope will lead to the development of preventative treatments for multiple...
Obesity is an aggravating factor in relapsing remitting multiple sclerosis (RRMS). A recent study by the Unit of Neurology and Neurorehabilitation of the Italian Ministry of Health as a Clinical...
Eleven-year-old Asher Walton-Mitchell from Sheffield has raised more than £1,300 after writing to 400 neighbours and asking them for help. Asher's neighbour Phil Waterworth, a former teacher who has...
Simvastatin, a widely prescribed cholesterol lowering drug, may slow brain atrophy and disease progression in secondary progressive multiple sclerosis (SPMS) for reasons unrelated to changes in blood...
Alterations in the composition of microbes in the gut may influence childhood MS. That’s according to research carried out by Dr. Helen Tremlett, PhD, of the University of British Columbia in Canada...
Treatment with Ocrevus (ocrelizumab) decreased levels of neurofilament light chain (NfL) and immune B-cells in the blood serum and central nervous system of patients with relapsing MS, according to...
Rates of sexual dysfunction and related distress are higher among women with MS than those without the condition. That is according to research published in the Journal of Sexual Medicine.
In the...
A new 48-week study of the investigational drug evobrutinib in patients with relapsing remitting MS (RRMS) showed it reduced the number of enhanced MRI lesions (T1 gadolinium-enhancing lesions) among...
The National Institute for Health and Care Excellence (NICE) has approved ocrelizumab (Ocrevus) for treating patients in England with early primary progressive multiple sclerosis (PPMS). Patients...
The European Medicines Agency (EMA) has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of a range of potentially serious side effects. These side...
